<div markdown='1'>

**Pulliam, JRC**, **SE Bellan** [p], M Gambhir, LA Meyers, and **J Dushoff**. (2015) [Evaluating Ebola vaccine trials: insights from simulation](http://www.sciencedirect.com/science/article/pii/S1473309915003035). _**The Lancet Infectious Diseases**_ 15(10): 1134. doi:10.1016/S1473-3099(15)00303-5

**Bellan, SE** [p], **JRC Pulliam**, CAB Pearson [p], D Champredon [g], SJ Fox [g], L Skrip [p], AP Galvani, M Gambhir, BA Lopman, **TC Porco**, LA Meyers, and **J Dushoff**. (2015) [Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis](http://dx.doi.org/10.1016/S1473-3099%2815%2970139-8). _**The Lancet Infectious Diseases**_ 15(6): 703-710. doi: 10.1016/S1473-3099(15)70139-8.

**Bellan, SE** [p], **J Dushoff**, AP Galvani, LA Meyers. (2015) [Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts](http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001801). _**PLoS Medicine**_ 12(3): e1001801. doi: 10.1371/journal.pmed.1001801

**Bellan, SE** [p], **JRC Pulliam**, **J Dushoff**, and LA Meyers. (2014) [Ebola control: effect of asymptomatic infection and acquired immunity](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961839-0/fulltext). _**The Lancet**_ 384(9953): 1499-1500. doi: 10.1016/S01406736(14)618390

**Bellan, SE** [p], **JRC Pulliam**, **J Dushoff**, and LA Meyers. (2014) [Ebola vaccine trials: the ethical mandate for a therapeutic safety net](http://bmj.com/cgi/content/full/bmj.g7518?ijkey=qHj1rqPkFuwxnAk&keytype=ref). _**The British Medical Journal**_ 349: g7518. doi: http://dx.doi.org/10.1136/bmj.g7518

</div>
